ArticleCureus2025
Recurrent Multi-territorial Ischemic Stroke As the Initial Presentation of Thrombotic Thrombocytopenic Purpura.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombotic thrombocytopenic purpura (TTP) is a rare hypercoagulable disorder characterized by fever, acute hemolytic anemia, thrombocytopenia, neurologic deficits, and renal failure. Due to the rarity of TTP, the infrequency of a complete TTP pentad, variable and atypical presentations, and overlap with other thrombotic microangiopathy, diagnosis is difficult to achieve. Here, we describe a middle-aged patient with recurrent multi-territory strokes, with the development of thrombocytopenia occurring later in the course of her illness without fever, hemolytic anemia, or renal failure. Etiologies for prior history of ischemic stroke were confounded by the presence of intrinsic cerebral arteriopathy at the bilateral anterior cerebral artery, middle cerebral artery, and posterior cerebral artery territories attributed to accelerated atherosclerosis from concurrent tobacco smoking and marijuana abuse. Extensive workup also disclosed inter-atrial shunt (grade III patent foramen ovale), which was subsequently treated with device closure for presumed secondary stroke prevention. Due to the development of thrombocytopenia and recurrent multi-territory strokes, an ADAMTS13 (a disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13) screen was ordered and was positive. The ADAMTS13 activity was <5%, while the ADAMTS13 inhibitor Bethesda titer was notably high (1.4, normal <0.4). For acute therapy, a three-day 1 mg/kg methylprednisolone was started, and a hematology service was consulted for co-management. The patient completed four rounds of plasmapheresis while receiving 90 mg of prednisone daily. She was then started on a regimen to complete four doses of weekly rituximab. The patient improved clinically during her stay, with noted improvements in platelet count and ADAMTS13 activity. In conclusion, thrombocytopenia may appear until later in the disease course with variant presentations of TTP. A low threshold to consider atypical etiologies when pursuing workup for cryptogenic stroke should be in mind when evaluating young adults with recurrent multi-territory ischemic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.